Biotechnology firm eGenesis has raised USD 191 million in a Series D funding round led by Lux Capital, with participation from existing investors such as ARCH Ventures, Khosla Ventures, and Fresenius Medical Care Ventures, among others, and new investors including DaVita and Eisai Innovation.

The raised funding is planned to be used for advancing the firm’s primary product candidate, EGEN-2784, toward a first-in-human study for kidney transplantation. The funds will be also channeled toward pipeline programs and broadening production capabilities.

eGenesis is a biotechnology company developing human-compatible engineered organs for transplantation. Its lead product candidate, EGEN-2784, is a genetically engineered pig kidney that carries three classes of edits: knockout of three genes involved in hyperacute rejection, insertion of seven human transgenes to modulate rejection pathways, and inactivation of endogenous retroviruses in the pig genome.

Analyst QuickTake: In March 2024 , eGenesis completed the world’s first successful xenotransplantation of a genetically modified pig kidney into a living patient. The transplant was authorized by the US FDA under the Expanded Access pathway and was performed at the Massachusetts General Hospital on a patient suffering from end-stage renal failure. The recipient passed away in May 2024, although the cause of death was deemed unrelated to the surgery.